SCHEMBL4770841

SCHEMBL4770841

Cc1ccc(F)cc1CN(c1ccc(N(C=O)Cc2ccc(C(F)(F)F)nc2)cc1)S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.37
CNR2 P34972 2/20 0.37
TRPA1 O75762 1/20 0.36
PER2 O15055 2/20 0.33
CRY1 Q16526 2/20 0.33
CRY2 Q49AN0 2/20 0.33
TRPM8 Q7Z2W7 3/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MAPT P10636 2/20 0.33
CYP3A4 P08684 1/20 0.32
RECQL P46063 1/20 0.32
P2RX7 Q99572 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571607 0.89 CNR1 (0.37) CNR1CNR2TRPA1PER2CRY1
SCHEMBL4771247 0.89 ALDH1A1 (0.42) CNR1CNR2TRPM8NR1H2NR1H3
SCHEMBL4770824 0.86 CNR1 (0.35) CNR1CNR2TRPA1TRPM8NR1H2
SCHEMBL4776637 0.86 RECQL (0.36) CNR1CNR2TRPM8NR1H2NR1H3
SCHEMBL4773593 0.85 CNR1 (0.36) CNR1CNR2SMN1; SMN2MAPTKCNH2
SCHEMBL4773365 0.84 LMNA (0.36) ALDH1A1SMN1; SMN2RECQL
SCHEMBL4770843 0.84 LMNA (0.36) CNR1CNR2NR1H2NR1H3ALDH1A1
SCHEMBL4777509 0.83 CNR2 (0.37) CNR1CNR2TRPM8NR1H2NR1H3
SCHEMBL4776872 0.83 RECQL (0.39) CNR1CNR2NR1H2NR1H3ALDH1A1
SCHEMBL4770892 0.83 LMNA (0.43) CNR1CNR2TRPM8NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 CNR1 4121/4885CNR2 4377/4885TRPA1 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.